A meta-analysis of the year-round vaccine persistency of trivalent inactivated influenza vaccine among elderly aged 65 years and above / 预防医学

ABSTRACT

Objective To evaluate the year-round vaccine persistency of trivalent inactivated influenza vaccine (TIV) among elderly aged 65 years and above. Methods Searching "National Center for Biotechnology Information" , "Cochrane Library, CL", "China Biology Medicine disc", "China National Knowledge Infrastructure", "Wanfang Database", the studies of the year-round vaccine persistency of trivalent inactivated influenza vaccine among the elderly aged 65 years and above were included, and meta-analysis were made by Stata 11.0 software. Results A total of 17 studies were included. Compared with the antibody level before immunization, the standard mean differences (SMDs) of geometric mean titer (GMT) was 0.10 (95%CI -0.12-0.32), 0.57 (95%CI 0.23-0.91), 0.47 (95%CI-0.20-1.15) and -0.27 (95%CI -0.51--0.04) for the total haemagglutination inhibition (HI) antibody, the HI antibody of A/H1N1, the HI antibody of A/H3N2 and the HI antibody of B, respectively, by 360 day. The risk differences (RD) of sero-protection rate (SP) was 0.06 (95%CI -0.04-0.16), 0.09 (95%CI -0.15-0.33), -0.08 (95%CI -0.28-0.13) and 0.00 (95%CI -0.13 - -0.13) for the total haemagglutination inhibition (HI) antibody, the HI antibody of A/H1N1, the HI antibody of A/H3N2 and the HI antibody of B, respectively, by 360 day. Conclusion The HI antibody responses following TIV vaccination do not reliably persist year-round in the elderly aged 65 years and above . Clinic trials and health economic evaluation studies are needed to assess the feasibility and cost-effectiveness of multiple doses schedule of TIV in elderly.